ResoTher Pharma is pleased to announce the following changes to its leadership team to further support the growth and development of the company.
Teis Vester, MSc., will take on the role of Chief Financial Officer from August 16th, 2021, replacing co-founder Jeppe Øvlesen, who will remain as a member of the Board of Directors. Teis has deep experience with financial strategy, planning and reporting within the biotech sector from previous roles at Symphogen, Atlab, and Basico and from his time as an auditor at Deloitte.
Thomas Jonassen, MD, will take on the role of Chief Medical Officer from September 1st 2021 to ensure a smooth and successful transition of our lead program into clinical development. Thomas is replacing Chief Development Officer Paul Hargreaves, MSc, MBA, who will be leaving ResoTher Pharma to pursue other opportunities.
Samra Sanni, PhD, will take on the role of Vice President, Drug Research from September 15th 2021 and will be responsible for preclinical drug research and development. Samra has a successful track record of peptide drug discovery within the cardio-metabolic space from her role as Director of Pharmacology at Bainan Biotech, and from her work with drug candidate validation and nomination at Antag Therapeutics and Novo Nordisk.
“We are very pleased to welcome Teis and Samra to our leadership team to support further development of ResoTher Pharma” stated Lone Veng, CEO of ResoTher Pharma. “They both bring significant experience from biotech and pharma companies and have solid track records of executing on strategic, financial and research objectives. Furthermore, with Thomas in charge of clinical development I am confident that we have the right team in place to deliver on ResoTher Pharma’s important mission – to validate our novel treatment concept for patients with Myocardial Infarct. Thomas´s long experience in early drug development and bringing drugs to proof of concept will be invaluable in this regard”.
Lone Veng further added “The company would also like to use this opportunity to thank Paul Hargreaves for his contributions. We wish him much success in his future endeavors”.